Biosimilars Market will be Worth $3.7 Billion by 2015
Biosimilars Market will be Worth $3.7 Billion by 2015
The global market for biosimilars is set to grow from $243 million in 2010 to $3.7 billion in 2015, according to research from Datamonitor, an independent industry analyst company.
One of the key drivers for growth will be the loss of patent exclusivity for many branded products. More than 30 branded biologics with sales of $51 billion will lose patent exclusivity by 2015, according to a statement from Datamonitor, which will pave the way for biosimilars.
“With the market shares of first-generation biologic drugs stagnating or declining, biosimilar MAbs and second-generation biosimilars represent a high-value proposition for biosimilars manufacturers and key drivers for future growth,” Mark Hollis, healthcare analyst at Datamonitor, explained in the statement.
However, Hollis also warned that there a number of barriers to achieving commercial success with biosimilars in the developed markets, even though biosimilar approval pathways are now in place in Europe, Japan and the US.
According to Datamonitor, existing biosimilars are well-positioned to take advantage of the predicted market growth because they already have an industry reputation, as well as relationships with key stakeholders. However, branded pharma companies may also be looking to leap into the biosimilars arena as a way of increasing sales. Partnerships and M&As are potential ways of achieving this.
Consequently, Datamonitor believes that the future biosimilars market will continue to be dominated by existing biosimilars players, with the addition of select, branded pharma companies. Companies in emerging markets may also make an appearance. Datamonitor adds: “Furthermore, emerging market biosimilars players are now looking to expand into global markets too, through partnerships with international pharma companies.”
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
